Clinical trials are strictly controlled studies of new and emerging therapies. At MD Anderson, these trials incorporate state-of-the-art of patient care, while carefully evaluating how best to apply the most recent developments in cancer medicine.
We have clinical trials for every stage bladder cancer. Some are appropriate for newly diagnosed patients who have not undergone treatment. Others involve patients who have already received specific types of treatment, or whose treatment may have failed.
Bladder cancer trials are conducted in MD Anderson's Genitourinary Care Center.
Rare bladder tumors
A Phase II, Randomized, Open Label, Parallel Arm Study to Evaluate the Safety and Efficacy of rAd-IFN/Syn3 Following Intravesical Administration in Subjects with High Grade, BCG Refractory, or Relapsed Non-Muscle Invasive Bladder Cancer (NMIBC)
This protocol seeks to evaluate the incidence of high-grade-recurrence-free survival at 12 months and to determine the time to progression to muscle-invasive disease.
Principal Investigator: Ashish Kamat
Protocol Number: 2012-0609